LYEL Lyell Immunopharma, Inc.
$11.96▼ -1.97%
Healthcare
Other
After hours
$11.96▲ +0.00%
Sep 11, 7:30 PM ET
Volume 152.2K
Avg Volume (10D) 78.1K
Key Metrics & Fundamentals
Market Cap
$293.08M
P/E Ratio
–
Div Yield
–%
52W Range
11.47 - 45.00
% vs 50 MA
-14.79%
% vs 200 MA
-40.77%
RSI-14
33.8
MACD Histogram
-0.3500
Beta (1Y vs SPY)
1.74
Free Cash Flow
-$34.18M
Gross Rev
$4,000
Gross Profit
$4,000
EBITDA
-$45.12M
COGS
–
Operating Exp
$47.34M
Operating Income
-$47.34M
EBIT
-$47.34M
Pretax Income
-$44.76M
Net Income
-$44.76M
EPS (Diluted)
-1.92
Price & Volume History
Loading chart…
Recent News
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
GlobeNewswire · Sep 10, 2026 8:05 PM
Lyell Immunopharma: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 9:39 PM
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
GlobeNewswire · Aug 6, 2026 8:05 PM
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · Aug 6, 2026 1:48 PM
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
24/7 Wall St. · Aug 6, 2026 11:59 AM
Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target
MT Newswires · Aug 6, 2026 11:18 AM
B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target
MT Newswires · Jul 22, 2026 11:58 AM
Lyell Immunopharma Files for Secondary Offering of Common Shares
MT Newswires · Jul 13, 2026 9:30 PM
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
Business Wire · Jul 6, 2026 1:00 PM
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
Zacks · Jul 2, 2026 1:55 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See LYEL's money flow as a full page
Social Sentiment
No Reddit posts found for LYEL.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.